Distribution of clinical and biologic risk factors in 58 patients with CLL according to VH mutation status
| . | Mutated, n = 20 . | Unmutated, n = 38 . | P* . |
|---|---|---|---|
| Age, y (range) | 49 (34-60) | 51 (29-64) | NS |
| Time to ASCT, mo (range) | 17 (5-109) | 16 (6-102) | NS |
| Upfront transplantation (%) | 17 (85) | 29 (76) | NS |
| Binet stage (%) | |||
| A | 8 (40) | 8 (21) | NS |
| B | 6 (30) | 21 (55) | NS |
| C | 6 (30) | 9 (23) | NS |
| LDT less than 12 mo (%) | 5/14 (20) | 24/28 (85) | .003 |
| High lymphocyte count (%) | 6/20 (30) | 26/37 (70) | .005 |
| del 11q−(%) | 1/17 (6) | 10/31 (32) | .07 |
| . | Mutated, n = 20 . | Unmutated, n = 38 . | P* . |
|---|---|---|---|
| Age, y (range) | 49 (34-60) | 51 (29-64) | NS |
| Time to ASCT, mo (range) | 17 (5-109) | 16 (6-102) | NS |
| Upfront transplantation (%) | 17 (85) | 29 (76) | NS |
| Binet stage (%) | |||
| A | 8 (40) | 8 (21) | NS |
| B | 6 (30) | 21 (55) | NS |
| C | 6 (30) | 9 (23) | NS |
| LDT less than 12 mo (%) | 5/14 (20) | 24/28 (85) | .003 |
| High lymphocyte count (%) | 6/20 (30) | 26/37 (70) | .005 |
| del 11q−(%) | 1/17 (6) | 10/31 (32) | .07 |
ASCT indicates autologous stem cell transplantation; and NS, not significant.
Fisher exact test.